Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Jérémy Bastid"'
Autor:
Maxime Annereau, Mélanie Hinterlang, Hugues Bienayme, Gilles Vassal, Antoine Pinon, Mathieu Schmitt, Lucas Denis, Caroline Lemarchand, Laurent Martin, François Lemare, Samuel Abbou, Jérémy Bastid, Lionel Tortolano
Publikováno v:
Pharmaceuticals, Vol 15, Iss 5, p 555 (2022)
The development of oral pediatric forms by pharmaceutical companies is still insufficient. In fact, many drugs used in paediatric oncology, such as temozolomide, are not labeled and adapted for paediatric use. Temozolomide (TMZ) is an alkylating agen
Externí odkaz:
https://doaj.org/article/012319936a1f415d825571ee184c0802
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Among inflammatory mediators, a growing body of evidence emphasizes the contribution of the interleukin 17 (IL-17) cytokine family in malignant diseases. Besides IL-17A, the prototypic member of the IL-17 family, several experimental findings strongl
Externí odkaz:
https://doaj.org/article/e3ad7366bac74d67b9640b7ed2a72ae5
Autor:
Ivan Perrot, Henri-Alexandre Michaud, Marc Giraudon-Paoli, Séverine Augier, Aurélie Docquier, Laurent Gros, Rachel Courtois, Cécile Déjou, Diana Jecko, Ondine Becquart, Hélène Rispaud-Blanc, Laurent Gauthier, Benjamin Rossi, Stéphanie Chanteux, Nicolas Gourdin, Beatrice Amigues, Alain Roussel, Armand Bensussan, Jean-François Eliaou, Jérémy Bastid, François Romagné, Yannis Morel, Emilie Narni-Mancinelli, Eric Vivier, Carine Paturel, Nathalie Bonnefoy
Publikováno v:
Cell Reports, Vol 27, Iss 8, Pp 2411-2425.e9 (2019)
Summary: Immune checkpoint inhibitors have revolutionized cancer treatment. However, many cancers are resistant to ICIs, and the targeting of additional inhibitory signals is crucial for limiting tumor evasion. The production of adenosine via the seq
Externí odkaz:
https://doaj.org/article/5587ee70bc8c4270948f7103cc944bcd
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 2 (2008)
Cancers have long been described as the result of successive selections of somatic cells progressively acquiring growth and survival advantages. Such a model was hardly compatible with the obvious heterogeneity of the cancer cell population present i
Externí odkaz:
https://doaj.org/article/ca01ca909be349e784e85abffe447032
Autor:
Marianne Quiding-Järbrink, Jérémy Bastid, Bengt Gustavsson, Lars Börjesson, Kamilla Fredin, Tapuka Gordon Ndah, Lisa Theander, Filip Ahlmanner, Veronica Langenes, Hanna Stenstad, Patrik Sundström
This supplementary figure shows the gating strategy to analyze T cell transendothelial migration (A), and the migration of CD4+ (B) and CD8+ T cells (C) after endothelial activation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cf9afca95e60299cb31bd2f90083060
https://doi.org/10.1158/2326-6066.22537279
https://doi.org/10.1158/2326-6066.22537279
Autor:
Marianne Quiding-Järbrink, Jérémy Bastid, Bengt Gustavsson, Lars Börjesson, Kamilla Fredin, Tapuka Gordon Ndah, Lisa Theander, Filip Ahlmanner, Veronica Langenes, Hanna Stenstad, Patrik Sundström
T cell–mediated immunity is a major component of antitumor immunity. In order to be efficient, effector T cells must leave the circulation and enter into the tumor tissue. Regulatory T cells (Treg) from gastric cancer patients, but not from healthy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f4d79cbdbe8319b93f7907bc0877226
https://doi.org/10.1158/2326-6066.c.6548377.v1
https://doi.org/10.1158/2326-6066.c.6548377.v1
Autor:
Ivan Perrot, Jérémy Bastid, Nathalie Bonnefoy, Jean-François Eliaou, Carine Paturel, Laurent Gros, Armand Bensussan
Publikováno v:
médecine/sciences
médecine/sciences, EDP Sciences, 2020, 36 (2), pp.112-115. ⟨10.1051/medsci/2020006⟩
médecine/sciences, EDP Sciences, 2020, 36 (2), pp.112-115. ⟨10.1051/medsci/2020006⟩
International audience; No abstract available
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee681302fb8f0ecd89223d4b5b9b92da
https://hal.archives-ouvertes.fr/hal-02903938
https://hal.archives-ouvertes.fr/hal-02903938
Autor:
Hélène Rispaud-Blanc, Jean-François Eliaou, Cécile Dejou, Rachel Courtois, Béatrice Amigues, Emilie Narni-Mancinelli, Nathalie Bonnefoy, Jérémy Bastid, Armand Bensussan, Marc Giraudon-Paoli, Aurélie Docquier, François Romagné, O. Becquart, Carine Paturel, Ivan Perrot, Benjamin Rossi, Yannis Morel, Laurent Gauthier, Henri-Alexandre Michaud, Laurent Gros, Eric Vivier, Nicolas Gourdin, Alain Roussel, Diana Jecko, Stéphanie Chanteux, Severine Augier
Publikováno v:
Cell Reports
Cell Reports, Elsevier Inc, 2019, 27 (8), pp.2411-2425. ⟨10.1016/j.celrep.2019.04.091⟩
Cell Reports, Vol 27, Iss 8, Pp 2411-2425.e9 (2019)
Cell Reports, Elsevier (Cell Press), 2019, 27 (8), pp.2411+. ⟨10.1016/j.celrep.2019.04.091⟩
Cell Reports, 2019, 27 (8), pp.2411-2425. ⟨10.1016/j.celrep.2019.04.091⟩
Cell Reports, Elsevier Inc, 2019, 27 (8), pp.2411-2425. ⟨10.1016/j.celrep.2019.04.091⟩
Cell Reports, Vol 27, Iss 8, Pp 2411-2425.e9 (2019)
Cell Reports, Elsevier (Cell Press), 2019, 27 (8), pp.2411+. ⟨10.1016/j.celrep.2019.04.091⟩
Cell Reports, 2019, 27 (8), pp.2411-2425. ⟨10.1016/j.celrep.2019.04.091⟩
Summary: Immune checkpoint inhibitors have revolutionized cancer treatment. However, many cancers are resistant to ICIs, and the targeting of additional inhibitory signals is crucial for limiting tumor evasion. The production of adenosine via the seq
Autor:
Jérôme Giustiniani, Christian Garbar, Armand Bensussan, Yacine Merrouche, Joseph Fabre, Jérémy Bastid, Hervé Curé, Camille Fuselier, Reem Al-Daccak, Frank Antonicelli
Publikováno v:
Oncotarget
Oncotarget, Impact journals, 2016, 7 (33), pp.53350-53361. ⟨10.18632/oncotarget.10804⟩
Oncotarget, Impact journals, 2016, 7 (33), pp.53350-53361. ⟨10.18632/oncotarget.10804⟩
International audience; Estrogen receptor-, progesterone receptor- and HER2-negative breast cancers, also known as triple-negative breast cancers (TNBCs), have poor prognoses and are refractory to current therapeutic agents, including epidermal growt
Autor:
Lisa Theander, Tapuka Gordon Ndah, Kamilla Fredin, Jérémy Bastid, Patrik Sundström, Lars Börjesson, Bengt Gustavsson, Veronica Langenes, Hanna Stenstad, Filip Ahlmanner, Marianne Quiding-Järbrink
Publikováno v:
Cancer Immunology Research. 4:183-193
T cell–mediated immunity is a major component of antitumor immunity. In order to be efficient, effector T cells must leave the circulation and enter into the tumor tissue. Regulatory T cells (Treg) from gastric cancer patients, but not from healthy